New antiretroviral drugs part I: PIs.

Robert Leo Murphy*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


This first installment of a two-part article on new antiretroviral drugs in development provides information on seven new protease inhibitors (PIs). The results of in vitro and in vivo trials are provided. Researchers hope these drugs will be more potent and effective, have favorable resistance profiles, and be better tolerated by patients. Featured PIs include ABT 378, tipranavir, and DMP 450.

Original languageEnglish (US)
Pages (from-to)35-37
Number of pages3
JournalAIDS clinical care
Issue number5
StatePublished - Jan 1 1999


Dive into the research topics of 'New antiretroviral drugs part I: PIs.'. Together they form a unique fingerprint.

Cite this